New Republic Capital LLC Lowers Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

New Republic Capital LLC cut its stake in Novo Nordisk A/S (NYSE:NVO) by 16.6% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,066 shares of the company’s stock after selling 611 shares during the period. New Republic Capital LLC’s holdings in Novo Nordisk A/S were worth $216,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Solidarity Wealth LLC purchased a new position in Novo Nordisk A/S in the first quarter valued at $802,000. Baldwin Investment Management LLC boosted its holdings in Novo Nordisk A/S by 2.6% in the first quarter. Baldwin Investment Management LLC now owns 22,315 shares of the company’s stock valued at $1,550,000 after purchasing an additional 575 shares during the period. Nemes Rush Group LLC boosted its holdings in Novo Nordisk A/S by 16.8% in the first quarter. Nemes Rush Group LLC now owns 97,116 shares of the company’s stock valued at $6,744,000 after purchasing an additional 13,951 shares during the period. Ridgewood Investments LLC boosted its holdings in Novo Nordisk A/S by 221.5% in the first quarter. Ridgewood Investments LLC now owns 2,170 shares of the company’s stock valued at $151,000 after purchasing an additional 1,495 shares during the period. Finally, LPL Financial LLC boosted its holdings in Novo Nordisk A/S by 1.7% in the first quarter. LPL Financial LLC now owns 1,379,207 shares of the company’s stock valued at $95,643,000 after purchasing an additional 23,140 shares during the period. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Down 3.8%

NVO opened at $68.98 on Tuesday. The business’s 50-day simple moving average is $70.71 and its 200-day simple moving average is $73.51. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.56 and a current ratio of 0.74. Novo Nordisk A/S has a one year low of $57.00 and a one year high of $139.74. The stock has a market capitalization of $308.00 billion, a P/E ratio of 20.41, a price-to-earnings-growth ratio of 1.38 and a beta of 0.64.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, hitting analysts’ consensus estimates of $0.92. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. The business had revenue of $11.87 billion for the quarter. Analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Wall Street Analysts Forecast Growth

NVO has been the subject of a number of recent research reports. BMO Capital Markets reiterated a “market perform” rating and issued a $64.00 target price (down from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Dbs Bank downgraded Novo Nordisk A/S to a “sell” rating in a report on Friday, April 25th. Guggenheim downgraded Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a report on Thursday, April 17th. Hsbc Global Res raised Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, April 28th. Finally, Wall Street Zen raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Saturday, June 14th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of “Hold” and a consensus target price of $112.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.